New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
09. Dezember 2023 12:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
05. Dezember 2023 17:26 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; December 5, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants. The...
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
27. November 2023 07:00 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
21. November 2023 16:45 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
21. November 2023 16:42 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,541 restricted stock units to members of the Board of...
Major Shareholder Announcement
09. November 2023 09:14 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 9, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Genmab to Present at Jefferies London Healthcare Conference
09. November 2023 05:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; November 9, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano...
Major Shareholder Announcement
08. November 2023 11:09 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 8, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Genmab Announces Financial Results for the First Nine Months of 2023
07. November 2023 11:01 ET
|
Genmab A/S
November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY®) was granted conditional marketing authorization by the...
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
02. November 2023 09:05 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; November 2, 2023 Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple...